Cargando…
Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma
BACKGROUND: Transarterial chemoembolization (TACE) is the standard treatment for hepatocellular carcinoma (HCC); the value of its combination with systemic therapy is worthy of further exploration. This study aimed to investigate the efficacy and safety of TACE combined with tyrosine kinase inhibito...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502547/ https://www.ncbi.nlm.nih.gov/pubmed/37720446 http://dx.doi.org/10.21037/jgo-23-486 |
_version_ | 1785106346569367552 |
---|---|
author | Hu, Yue Pan, Tao Cai, Xi He, Quan-Sheng Zheng, Yu-Bao Huang, Ming-Sheng Jiang, Zai-Bo Chen, Jun-Wei Wu, Chun |
author_facet | Hu, Yue Pan, Tao Cai, Xi He, Quan-Sheng Zheng, Yu-Bao Huang, Ming-Sheng Jiang, Zai-Bo Chen, Jun-Wei Wu, Chun |
author_sort | Hu, Yue |
collection | PubMed |
description | BACKGROUND: Transarterial chemoembolization (TACE) is the standard treatment for hepatocellular carcinoma (HCC); the value of its combination with systemic therapy is worthy of further exploration. This study aimed to investigate the efficacy and safety of TACE combined with tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) in the treatment of unresectable HCC. METHODS: In this retrospective observational, single-center study, 147 patients with unresectable HCC were divided into a TACE group (n=98) and a non-TACE group (n=49) based on whether TACE was performed during TKI plus ICI therapy. The survival outcomes and adverse events (AEs) of the two groups were compared. RESULTS: Data from patients with unresectable HCC who received TKI plus ICI treatment between July 2017 and April 2020 were collected. The median intrahepatic tumor size was 8.7 cm [interquartile range (IQR), 5.9–12.4 cm]. At data cut-off, overall survival (OS) of the TACE group was significantly longer than that of the non-TACE group (19.5 and 10.8 months, respectively, P=0.005). In the high-risk cohort (with main or contralateral portal vein tumor thrombi and/or bile duct invasion and/or a tumor burden >50% of liver), the OS of the TACE group was still longer than that of the non-TACE group (14.9 and 8.7 months, respectively, P=0.031). Major AEs were tolerated in both groups, and there was no significant difference in their incidence (34.7% and 30.6%, respectively, P=0.621). CONCLUSIONS: TACE treatment combined with TKI plus ICI regime resulted in longer OS than treatment with TKI plus ICI alone for patients with unresectable HCC. |
format | Online Article Text |
id | pubmed-10502547 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-105025472023-09-16 Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma Hu, Yue Pan, Tao Cai, Xi He, Quan-Sheng Zheng, Yu-Bao Huang, Ming-Sheng Jiang, Zai-Bo Chen, Jun-Wei Wu, Chun J Gastrointest Oncol Original Article BACKGROUND: Transarterial chemoembolization (TACE) is the standard treatment for hepatocellular carcinoma (HCC); the value of its combination with systemic therapy is worthy of further exploration. This study aimed to investigate the efficacy and safety of TACE combined with tyrosine kinase inhibitor (TKI) and immune checkpoint inhibitor (ICI) in the treatment of unresectable HCC. METHODS: In this retrospective observational, single-center study, 147 patients with unresectable HCC were divided into a TACE group (n=98) and a non-TACE group (n=49) based on whether TACE was performed during TKI plus ICI therapy. The survival outcomes and adverse events (AEs) of the two groups were compared. RESULTS: Data from patients with unresectable HCC who received TKI plus ICI treatment between July 2017 and April 2020 were collected. The median intrahepatic tumor size was 8.7 cm [interquartile range (IQR), 5.9–12.4 cm]. At data cut-off, overall survival (OS) of the TACE group was significantly longer than that of the non-TACE group (19.5 and 10.8 months, respectively, P=0.005). In the high-risk cohort (with main or contralateral portal vein tumor thrombi and/or bile duct invasion and/or a tumor burden >50% of liver), the OS of the TACE group was still longer than that of the non-TACE group (14.9 and 8.7 months, respectively, P=0.031). Major AEs were tolerated in both groups, and there was no significant difference in their incidence (34.7% and 30.6%, respectively, P=0.621). CONCLUSIONS: TACE treatment combined with TKI plus ICI regime resulted in longer OS than treatment with TKI plus ICI alone for patients with unresectable HCC. AME Publishing Company 2023-08-14 2023-08-31 /pmc/articles/PMC10502547/ /pubmed/37720446 http://dx.doi.org/10.21037/jgo-23-486 Text en 2023 Journal of Gastrointestinal Oncology. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Hu, Yue Pan, Tao Cai, Xi He, Quan-Sheng Zheng, Yu-Bao Huang, Ming-Sheng Jiang, Zai-Bo Chen, Jun-Wei Wu, Chun Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma |
title | Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma |
title_full | Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma |
title_fullStr | Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma |
title_full_unstemmed | Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma |
title_short | Addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma |
title_sort | addition of transarterial chemoembolization improves outcome of tyrosine kinase and immune checkpoint inhibitors regime in patients with unresectable hepatocellular carcinoma |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502547/ https://www.ncbi.nlm.nih.gov/pubmed/37720446 http://dx.doi.org/10.21037/jgo-23-486 |
work_keys_str_mv | AT huyue additionoftransarterialchemoembolizationimprovesoutcomeoftyrosinekinaseandimmunecheckpointinhibitorsregimeinpatientswithunresectablehepatocellularcarcinoma AT pantao additionoftransarterialchemoembolizationimprovesoutcomeoftyrosinekinaseandimmunecheckpointinhibitorsregimeinpatientswithunresectablehepatocellularcarcinoma AT caixi additionoftransarterialchemoembolizationimprovesoutcomeoftyrosinekinaseandimmunecheckpointinhibitorsregimeinpatientswithunresectablehepatocellularcarcinoma AT hequansheng additionoftransarterialchemoembolizationimprovesoutcomeoftyrosinekinaseandimmunecheckpointinhibitorsregimeinpatientswithunresectablehepatocellularcarcinoma AT zhengyubao additionoftransarterialchemoembolizationimprovesoutcomeoftyrosinekinaseandimmunecheckpointinhibitorsregimeinpatientswithunresectablehepatocellularcarcinoma AT huangmingsheng additionoftransarterialchemoembolizationimprovesoutcomeoftyrosinekinaseandimmunecheckpointinhibitorsregimeinpatientswithunresectablehepatocellularcarcinoma AT jiangzaibo additionoftransarterialchemoembolizationimprovesoutcomeoftyrosinekinaseandimmunecheckpointinhibitorsregimeinpatientswithunresectablehepatocellularcarcinoma AT chenjunwei additionoftransarterialchemoembolizationimprovesoutcomeoftyrosinekinaseandimmunecheckpointinhibitorsregimeinpatientswithunresectablehepatocellularcarcinoma AT wuchun additionoftransarterialchemoembolizationimprovesoutcomeoftyrosinekinaseandimmunecheckpointinhibitorsregimeinpatientswithunresectablehepatocellularcarcinoma |